Cumulative Probability of Prostate Cancer Detection Using the International Prostate Symptom Score in a Prostate-specific Antigen-based Population Screening Program in Japan |
Kitagawa, Yasuhide
(Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University)
Urata, Satoko (Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University) Narimoto, Kazutaka (Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University) Nakagawa, Tomomi (Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University) Izumi, Kouji (Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University) Kadono, Yoshifumi (Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University) Konaka, Hiroyuki (Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University) Mizokami, Atsushi (Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University) Namiki, Mikio (Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University) |
1 | Bouchardy C, Fioretta G, Rapiti E, et al (2008). Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer, 123, 421-9. DOI |
2 | Brown CT, O'Flynn E, van der Meulen J, et al (2003). The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened? BJU Int, 91, 30-2. DOI ScienceOn |
3 | Franlund M, Carlsson S, Stranne J, Aus G, Hugosson J (2012). The absence of voiding symptoms in men with a prostatespecific antigen (PSA) concentration of 3.0ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg randomized screening trial. BJU Int, 110, 638-43. DOI |
4 | Gretzer MB, Partin AW (2003). PSA markers in prostate cancer detection. Urol Clin North Am, 30, 677-86. DOI |
5 | Hochberg DA, Armenakas NA, Fracchia JA (2000). Relationship of prostate-specific antigen and prostate volume in patients with biopsy proven benign prostatic hyperplasia. Prostate, 45, 315-9. DOI |
6 | International Union Against Cancer (1997). Urologic Tumors: Prostate. In 'TNM Classification of Malignant Tumours. 5th ed.' Eds Sobin LH and Wittekind CH. John Wiley & Sons, New York pp170-3 |
7 | Ito K (2009). Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives. Int J Urol, 16, 458-64. DOI |
8 | Ito M, Masuda H, Kawakami S, et al (2013). Impact of lower urinary tract symptoms on prostate cancer risk among Japanese men with prostate-specific antigen <10ng/ml and non-suspicious digital rectal examination. Int J Urol, 20, 1163-8. DOI |
9 | Kash DP, Lal M, Hashmi H, Mubarak M (2014). Utility of digital rectal examination, serum prostate specific antigen, and transrectal ultrasound in the detection of prostate cancer: a developing country perspective. Asian Pac J Cancer Prev, 15, 3087-91. 과학기술학회마을 DOI |
10 | Kitagawa Y, Mizokami A, Nakashima K, et al (2011). Clinical outcomes of prostate cancer patients detected by prostatespecific antigen-based population screening in Kanazawa city, Japan. Int J Urol, 18, 592-6. DOI |
11 | Kitagawa Y, Mizokami A, Namiki M (2013). Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening. Prostate Int, 1, 65-8. DOI |
12 | Kobori Y, Kitagawa Y, Mizokami A, et al (2008). Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1-10.0ng/ml as a criterion. Int J Clin Oncol, 13, 229-32. DOI |
13 | Kubota Y, Ito K, Imai K, et al (2002). Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate, 50, 262-9. DOI |
14 | Matsubara A, Yasumoto H, Teishima J, et al (2006). Lower urinary tract symptoms and risk of prostate cancer in Japanese men. Int J Urol, 13, 1098-102. DOI ScienceOn |
15 | Mochtar CA, Kiemeney LA, van Riemsdijk MM, et al (2003). Prostate-specific antigen as estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol, 44, 695-700. DOI ScienceOn |
16 | Okihara K, Kitamura K, Okada K, et al (2008). Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan. Int J Urol, 15, 156-61. DOI ScienceOn |
17 | Young JM, Muscatello DJ, Ward JE (2000). Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Int, 85, 1037-48. DOI |
18 | Schulman CC, Kirby R, Fitzpatrick JM (2003). Awareness of prostate cancer among the general public: findings of an independent international survey. Eur Urol, 44, 294-302. DOI |
19 | Shin S, Kim YH, Hwang JS, et al (2014). Economic evaluation of prostate cancer screening test as a national cancer screening program in South Korea. Asian Pac J Cancer Prev, 15, 3383-9. 과학기술학회마을 DOI |
20 | Verim L, Yildirim A, Basok EK, et al (2013). Impact of PSA and DRE on histologic findings at prostate biopsy in Turkish men over 75 years of age. Asian Pac J Cancer Prev, 14, 6085-8. 과학기술학회마을 DOI ScienceOn |
21 | Zheng XY, Zhang P, Xie LP, et al (2012). Prostate-specific antigen velocity (PSAV) and PSAV per initial volume (PSADV) for early detection of prostate cancer in Chinese men. Asian Pac J Cancer Prev, 13, 5529-33. 과학기술학회마을 DOI ScienceOn |
22 | Kwon HT, Ma GX, Gold RS, Atkinson NL, Wang MQ (2013). Primary care physician's cancer screening recommendation practices and perceptions of cancer risk of Asian Americans. Asian Pac J Cancer Prev, 14, 1999-2004. 과학기술학회마을 DOI ScienceOn |